此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy

2016年8月29日 更新者：Genzyme, a Sanofi Company

Randomized, Double-blinded, Placebo-controlled Phase II Study of Vandetanib (ZactimaTM) Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy

This study is multicenter, randomized, double-blinded, placebo-controlled Phase II study comparing vandetanib (300mg daily) plus best supportive care (BSC) to placebo plus BSC as maintenance treatment in patients with locally advanced or metastatic NSCLC, who have received and responded to prior platinum-doublet systemic chemotherapy. The primary objective of the study is to compare the Progression Free Survival (PFS) rate at 3 months in locally advanced or metastatic NSCLC patients with or without vandetanib maintenance.

研究概览

地位

完全的

条件

干预/治疗

研究类型

介入性

注册 (实际的)

117

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 大韩民国
    • Republic of Korea
      • CheongJu、Republic of Korea、大韩民国
        • Research Site
      • Gyeonggi-do、Republic of Korea、大韩民国
        • Research Site
      • Gyeongsangnam-Do、Republic of Korea、大韩民国
        • Research Site
      • Incheon、Republic of Korea、大韩民国
        • Research Site
      • Seoul、Republic of Korea、大韩民国
        • Research Site

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histologic or cytologic confirmation of locally advanced or metastatic NSCLC (IIIb-IV) at the time of original diagnosis.
  • Completion of 4 cycles of chemotherapy of gemcitabine (1,000 or 1250mg/m^2/day on day 1 and 8) and cisplatin (70-80mg/m^2/day on day 1) every 3 weeks and have shown response, Complete Response(CR), Partial Response (PR) or stable disease (SD) by RECIST.
  • WHO PS 0-1
  • No prior radiotherapy to chest, immunotherapy or biologic therapy

Exclusion Criteria:

  • Mixed small cell and non small-cell lung cancer history.
  • Prior treatment with EGFR TKIs or VEGFR TKIs (prior treatment with cetuximab [Erbitux] or bevacizumab [Avastin] is not permitted.)
  • Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol.
  • Radiation therapy within 4 weeks before the start of study therapy. Major surgery within 4 weeks, or incomplete healed surgical incision before starting study therapy.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：双倍的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较：安慰剂
药品：安慰剂
安慰剂
实验性的：Vandetanib
药品：Vandetanib
Tablet, oral, daily
其他名称：
  • Zactima TM

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Progression-free Survival (PFS) Rate at 3 Months
大体时间：12 weeks
Progression-free survival (PFS) rate at 3 months is defined as the number of patients without evidence of progression or death after 3 months from randomisation among the PFS-evaluable patients.
12 weeks

次要结果测量

结果测量
措施说明
大体时间
Progression-free Survival (PFS)
大体时间：Performed at baseline, every 4 weeks until Week 12 following randomization and then every 8 weeks until objective disease progression.
Progression-free survival (PFS) defined as the median time from randomization to death from any cause or first observed disease progression.
Performed at baseline, every 4 weeks until Week 12 following randomization and then every 8 weeks until objective disease progression.
Overall Survival (OS)
大体时间：Every 12 weeks unless the patient withdraws consent
Overall survival (OS) defined as the median time from randomization to death from any cause.
Every 12 weeks unless the patient withdraws consent
Disease of Response (DOR)
大体时间：Performed at baseline, every 4 weeks until Week 12 following randomization and then every 8 weeks until objective disease progression.

Number of patients showing Complete Response (CR), Partial Response (PR) or Stable Disease (SD) based on RECIST for the best response.

Number of patients showing Complete Response (CR, disappearance of all target lesions), Partial Response (PR, at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter) or Stable Disease (SD, Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum longest diameter since the treatment started) based on RECIST Criteria Version 1.0 (assessed by CT and/or MRI) for the best response
Performed at baseline, every 4 weeks until Week 12 following randomization and then every 8 weeks until objective disease progression.
Objective Response Rate (ORR)
大体时间：Performed at baseline, every 4 weeks until Week 12 following randomization and then every 8 weeks until objective disease progression.

Number of patients showing Complete Response (CR) or Partial Response (PR) based on RECIST for the best response.

Number of patients showing Complete Response (CR, disappearance of all target lesions) or Partial Response (PR, at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter) based on RECIST Criteria Version 1.0 (assessed by CT and/or MRI) for the best response.
Performed at baseline, every 4 weeks until Week 12 following randomization and then every 8 weeks until objective disease progression.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Genzyme, a Sanofi Company

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2008年10月1日

初级完成 (实际的)

2010年1月1日

研究完成 (实际的)

2011年12月1日

研究注册日期

首次提交

2008年10月21日

首先提交符合 QC 标准的

2008年10月21日

首次发布 (估计)

2008年10月22日

研究记录更新

最后更新发布 (估计)

2016年10月10日

上次提交的符合 QC 标准的更新

2016年8月29日

最后验证

2016年8月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • D4200C00077

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

非小细胞肺癌的临床试验

安慰剂的临床试验

搜索类似试验

赞助者和合作者

医疗条件

药物干预

CROs by country

CROs in Lithuania

条件

罕见疾病

药物干预

膳食补充剂

赞助者/合作者

地点

3
订阅